A cross-sectional, descriptive and analytical study was conducted from January to August 2015 at the Brazzaville Ambulatory Treatment Center and at？the National Blood Transfusion Center. The objective was to contribute to improving？the care of people living with HIV under antiretroviral therapy by assessing their global cardiovascular risk (CVR). The variables studied focused on the epidemiological, clinical and biological aspects. The global CVR was assessed？by the Framingham and WHO/ISH scores. There were 135 HIV-positive subjects,？including 64 treated patients and 71 untreated HIV+ subjects. The subjects were divided into 83 men (61.5%) and 52 women (38.5%), with an average age of 42.6 ± 2.9 old years. The subjects were single people (62.2%), of a secondary educational level (63.7%), and civil servants (32.6%). The main risk factors found were dyslipidaemia (60%), obesity (36%), smoking (12.6%), hypertension (5.9%), diabetes (0.7%). The metabolic syndrome was found in seven cases (11.3%). The global CVR according to the score of Framingham, initially moderated at 17.2%, and mean at 1.5% within treated patients, was mean at 9.4% and high at 1.6% of the subjects respectively at the sixth month of treatment (p < 0.03). For the score of the WHO/ISH, the risk was high at 2% and very high at 3% within treated patients initially. This risk was increased to 3.1% for the high and very high risk respectively at sixth month of treatment (p < 0.04). In Congo, the HIV population involves a high global？CVR under antiretroviral therapy. Preventive actions are highly recommended.
References
[1]
Rapport ONUSIDA sur l’épidémiologiemondiale (2014). http://www.who.org
[2]
How AIDS Changed Everything: OMD 6: 15 ans, 15 leconsd’espoir de la riposte au SIDA. http://www.who.org
[3]
Rapport d’activités 2015 sur la riposte au SIDA dans le monde.
http://www.unaids.org
[4]
République du Congo (2010) Programme National de Luttecontre le SIDA, UNICEF, OMS, Guide thérapeutique de prise en charge du VIH/SIDA. 35-40.
[5]
Centre National de la Statistiqueet des Etudes Economiques (2009) Enquête sur la séroprévalenceet les indicateurs du SIDA au Congo (ESISC-1) 2009: Rapport de synthèse. Brazzaville, 1-11.
[6]
Boccara, F. (2008) Cardiovascular Complications and Atherosclerotic Manifestations in the HIV-Infected Population: Type, Incidence and Associated Risk Factors. AIDS, 3, S19-S26. https://doi.org/10.1097/01.aids.0000327512.76126.6e
[7]
Boccara, F., Capeau, J., Caron, M., Vigouroux, C. and Cohen, A. (2009) VIH, antirétroviraux, dyslipidémie et risque cardiovasculaire. Médecine et Maladies Infectieuses, 3, 59-64. https://doi.org/10.1016/S1957-2557(09)70106-3
[8]
Zimmet, P., Magliano, D., Matsuzawa, Y., Alberti, G. and Shaw, J. (2005) The Metabolic Syndrome: A Global Public Health Problem and a New Definition. Journal of Atherosclerosis and Thrombosis, 12, 295-300. https://doi.org/10.5551/jat.12.295
[9]
D’Agostino, R.B., Vasan, R.S., Pencina, M.J., et al. (2008) General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation, 117, 743-753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579
[10]
World Health Organization (2007) Prevention of Cardiovascular Diseases Guidelines of Assessment and Management of Cardiovascular Risk. WHO, Geneva.
[11]
Kwong, G.P., Ghani, A.C., Rode, R.A., et al. (2006) Comparison of the Risks of Atherosclerotic Events versus Death from Others Causes Associated with Antiretroviral Use. AIDS, 20, 1941-1950.
https://doi.org/10.1097/01.aids.0000247115.81832.a1
[12]
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G.R., Chisholm, D.J. and Cooper, D.A. (1999) Diagnosis, Prediction, and Natural Course of HIV-1 Protease-Inhibitor-Associated Lipodystrophy, Hyperlipidaemia, and Diabetes Mellitus: A Cohort Study. The Lancet, 353, 2093-2099. https://doi.org/10.1016/S0140-6736(98)08468-2
[13]
Piériard, D., Telenti, A., Sudre, P., et al. (1999) Atherogenic Dyslipidemia in HIV-Infected Individuals Treated with Protease Inhibitors. The Swiss HIV Cohort Study. Circulation, 100, 700-705. https://doi.org/10.1161/01.CIR.100.7.700
[14]
Thiébaut, R., Savès, M., Mercié, P., Cipriano, C., Chêne, G. and Dabis, F. (2003) Epidémiologie du risquevasculaired’origineathéroscléreuse chez les patients infectés par le VIH-1. La Presse Médicale, 32, 1419-1426.
[15]
David, M.H., Hornung, R. and Fichtenbaum, C.J. (2002) Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 34, 98-102. https://doi.org/10.1086/324745
[16]
Bergersen, B.M., Sandvik, L., Bruun, J.N. and Tonstad, S. (2004) Elevated Framingham Risk Score in HIV-Positive Patients on Highly Active Antiretroviral Therapy: Results from a Norwegian Study of 721 Subjects. European Journal of Clinical Microbiology & Infectious Diseases, 23, 625-630.
https://doi.org/10.1007/s10096-004-1177-6
[17]
Neumann, T., Woiwod, T., Neumann, A., et al. (2004) Cardiovascular Risk Factors and Probability for Cardiovascular Events in HIV-Infected Patients Part III: Age Differences. European Journal of Medical Research, 9, 267-272.
[18]
Saves, M., Chêne, G., Ducimetiere, P., et al. (2003) Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population. Clinical Infectious Diseases, 37, 292-298.
https://doi.org/10.1086/375844
[19]
Friis-Moller, N., Weber, R., Reiss, P., et al. (2003) Cardiovascular Disease Risk Factors in HIV Patients—Association with Antiretroviral Therapy. Results from the DAD Study. AIDS, 17, 1179-1193. https://doi.org/10.1097/00002030-200305230-00010
[20]
Friis-Moller, N., Sabin, C.A., Weber, R., et al. (2003) Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The New England Journal of Medicine, 349, 1993-2003. https://doi.org/10.1056/NEJMoa030218
[21]
Sawadogo, A., Sanou, S., Hema, A., et al. (2014) Metabolic Syndrome and Cardiovascular Risk Patients under Antiretrovirals in a Day Hospital at Bobo-Dioulasso (Burkina Faso). Bulletin de la Société de Pathologie Exotique, 107, 151-158.
https://doi.org/10.1007/s13149-014-0371-8
[22]
Diouf, A. and Cournil, A. (2014) Prevalence of Metabolic Complications after 10 Years of Antiretroviral Treatment in Senegal. Bulletin de la Société de Pathologie Exotique, 107, 234-237. https://doi.org/10.1007/s13149-014-0349-6
[23]
Zannou, D.M., Tchabi, Y., Ahomadegbé, C., et al. (2013) Risquecardiovasculaire chez les personnes vivant avec le VIH à l’hopitaluniversitaire de Cotonou, Bénin. Medecine d’Afrique Noire, 60, 419-426.
[24]
Manuthu, E.M., Joshi, M.D., Lule, G.N. and Karari, E. (2008) Prevalence of Dyslipidemia and Dysglycaemia in HIV Infected Patients. East African Medical Journal, 85, 10-17. https://doi.org/10.4314/eamj.v85i1.9600
[25]
Alassani, A., Dovonou, A.C., Sossou, E., et al. (2015) Prévalence, facteurs associés et prédisposant du syndrome métabolique chez les personnes vivant avec le VIH sous traitement antirétroviral à Porto-Novo en 2014. Pan African Medical Journal, 22, 296. https://doi.org/10.11604/pamj.2015.22.296.7923
[26]
Mercié, P., Tchamgoué, S., Thiébaut, R., et al. (2000) Atherogen Lipid Profile in HIV-1 Infected Patients with Lipodystrophy Syndrome. European Journal of Internal Medicine, 11, 257-263. https://doi.org/10.1016/S0953-6205(00)00103-5
[27]
Carr, A. and Cooper, D.A. (2000) Adverse Effects of Antiretroviral Therapy. The Lancet, 356, 1423-1430. https://doi.org/10.1016/S0140-6736(00)02854-3
[28]
Thiébaut, R., Daucourt, V., Mercié, P., et al. (2000) Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999. Grouped Epidémiologie Clinique du Syndrome d’Immunodéficience Acquiseen Aquitaine. Clinical Infectious Diseases, 31, 1482-1487.
https://doi.org/10.1086/317477
[29]
Mooser, V. and Carr, A. (2001) Antiretroviral Therapy-Associated Hyperlipidaemia in HIV Disease. Current Opinion in Lipidology, 12, 313-319.
https://doi.org/10.1097/00041433-200106000-00011
[30]
Kaplan, R.C., Kingsley, L.A., Sharrett, A.R., et al. (2007) Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women. Clinical Infectious Diseases, 45, 1074-1081. https://doi.org/10.1086/521935
[31]
Lake, J.E. and Currier, J.S. (2013) Metabolic Disease in HIV Infection. The Lancet Infectious Diseases, 13, 964-975. https://doi.org/10.1016/S1473-3099(13)70271-8
[32]
Mary-Krause, M., Cotte, L., Simon, A., Partisani, M. and Costagliola, D. (2003) Increased Risk of Myocardial Infarction with Duration of Protease Inhibitor Therapy in HIV-Infected Men. AIDS, 17, 2479-2486.
https://doi.org/10.1097/00002030-200311210-00010
